ReviewGynecologic oncology reports2025
Embryonal rhabdomyosarcoma of the uterine corpus in a postmenopausal Woman: A case report and literature Review.
Review in Gynecologic oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Rhabdomyosarcoma (RMS) is a rare malignant mesenchymal tumor, primarily affecting children. Occurrence in the uterine corpus of adults, particularly postmenopausal women, is extremely uncommon. Case Presentation: A 60-year-old postmenopausal nulligravid woman presented with abnormal genital bleeding for three months. Pelvic examination revealed a friable mass extending from the uterine corpus. Biopsy confirmed embryonal RMS. She underwent modified radical hysterectomy with bilateral salpingo-oophorectomy for complete surgical resection. One cycle of adjuvant VAC chemotherapy (vincristine, actinomycin D, and cyclophosphamide) was administered but discontinued at her request. No residual disease was observed postoperatively, and she remains disease-free 12 months after surgery. Conclusion: Adult-onset uterine corpus embryonal RMS is rare, and standardized treatment protocols are lacking. Early diagnosis, complete surgical resection, and individualized therapy are essential. A literature review highlights clinical characteristics, treatment strategies, and prognostic considerations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.